Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Immunoclin CorpFinancial_Report.xls
10-K - FORM 10-K ANNUAL REPORT - Immunoclin Corpf10k022912_10k.htm
XML - IDEA: XBRL DOCUMENT - Immunoclin CorpR6.htm
XML - IDEA: XBRL DOCUMENT - Immunoclin CorpR3.htm
XML - IDEA: XBRL DOCUMENT - Immunoclin CorpR4.htm
XML - IDEA: XBRL DOCUMENT - Immunoclin CorpR8.htm
XML - IDEA: XBRL DOCUMENT - Immunoclin CorpR1.htm
XML - IDEA: XBRL DOCUMENT - Immunoclin CorpR9.htm
XML - IDEA: XBRL DOCUMENT - Immunoclin CorpR5.htm
XML - IDEA: XBRL DOCUMENT - Immunoclin CorpR2.htm
XML - IDEA: XBRL DOCUMENT - Immunoclin CorpR12.htm
XML - IDEA: XBRL DOCUMENT - Immunoclin CorpR10.htm
XML - IDEA: XBRL DOCUMENT - Immunoclin CorpR11.htm
EX-31.2 - EXHIBIT 31.2 SECTION 302 CERTIFICATION - Immunoclin Corpf10k022912_ex31z2.htm
EX-32.1 - EXHIBIT 32.1 SECTION 906 CERTIFICATION - Immunoclin Corpf10k022912_ex32z1.htm
EX-31.1 - EXHIBIT 31.1 SECTION 302 CERTIFICATION - Immunoclin Corpf10k022912_ex31z1.htm
v2.4.0.6
Nature of Operations and Continuance of Business
12 Months Ended
Feb. 29, 2012
Nature of Operations and Continuance of Business  
Nature of Operations and Continuance of Business

1.

Nature of Operations and Continuance of Business

 

Pharma Investing News, Inc. (the “Company”) was incorporated in the State of Nevada on February 8, 2011. The Company is a Development Stage Company, as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915, Development Stage Entities.

 

Going Concern

 

These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of February 29, 2012, the Company has not recognized any revenue, and has a working capital deficit and an accumulated deficit of $90,697. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.  These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.